Film Adaptation Of ‘Dear Evan Hansen’ Coming Soon
By: Nick Sawicki
The trailer for the film adaptation of Dear Evan Hansen has been released. The movie is an adaptation of the Tony Award-winning musical. The movie expected to arrive in September is about Evan Hansen, a high school senior with Social Anxiety disorder and his journey of self-discovery and acceptance following the suicide of a fellow classmate.
(ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute treatment of Social Anxiety Disorder (SAD) while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder (PTSD).
BNC210 is a novel, first-in-class, negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders. In November 2019 it was granted Fast Track designation by the US FDA for the treatment of PTSD.
The company said a previous successful Phase 2a study in GAD patients demonstrated that acute administration of the liquid suspension formulation of BNC210 had significant anti-anxiety effects as measured in brain imaging and behavioural studies similar to benzodiazepines but without evidence for sedation or addictive potential.
Bionomics BNC210 Expansion into Social Anxiety Disorder
News provided by
Share this article
Share this article
Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder
BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research selected and clinical site identification underway
Pipeline expansion puts Company on path for two Phase 2 programs underway in 2021
ADELAIDE, Australia, May 10, 2021 /PRNewswire/ Bionomics Limited (OTCQB:BNOEF) (
Bionomics or
Company), a global, clinical stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety efficacy signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder (SAD) while progressing toward the start of its planned
Cognitive-Behavioral Strategies to Manage Anxiety: May 2021
AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals 3.00 CME Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Cognitive-Behavioral Treatment for Generalized Anxiety Disorder: Theoretical Foundations and Empirically Supported Strategies